Consejo Superior de Investigaciones Científicas posted this:In vitro method for designing a customized therapy for a subject with Parkinson´sDisease CSIC, Université de Lille, INSERM and Centre Hospitalier Regional Universitaire de Lille have developed an in vitro method for designing a customized therapy for a Parkinson ‘s Disease patient through the determination of the presence of a centrosomal deficit from that subject and therefore susceptible to receive a therapy based on a LRRK2 inhibitor. LRRK2 is a key player for the development of both genetic and sporadic forms of Parkinson’s Disease (PD). Industrial partners from pharmaceutical industry are being sought to collaborate through a patent licence agreement.
Yissum - Research Development Company of the Hebrew University posted this:Takeover Detection for Cyber Defense at the Industrial Control Systemsdetection of a cyber takeover of the monitored Industrial Control Systems and critical infrastructures, even in the presence of successful sensor hijacking Project ID : 46-2019-10804
Execom posted this:Execom IoT expertise - the perfect team to make your devices smartExecom - The perfect IoT partner to make your devices smart. Focusing on development in IoT area, our R&D department was founded in 2012. Today, we have a spin off company called WolkAbout which has developed its own smart IoT platform, but our IoT department is working in the same discipline, as well. Besides the platform, we have experience in working with AWS IoT and Microsoft Azure IoT. The main focus of Execom IoT department is the embedded part of IoT solutions, but we do not shy away from custom cloud implementation either.
LUCIA CORAL posted this:
Knowledge Tranfer Manager at National Cancer Institute CRO Aviano
University of Granada (OTRI) posted this:Method for diagnosing Hereditary Hemorrhagic Telangiectasia (HHT)Hereditary Hemorrhagic Telangiectasia (HHT) is a rare and genetic disease in which a disorder in angiogenesis exists. A new method for the molecular diagnosis of this disease has been developed. It is based on the quantification of a set of microRNAs (miRNAs) transported by plasma exosomes, and in addition, this set allows diagnosing different variants of the disease. This new method has the advantage of providing new biomarkers that allow a rapid and reliable diagnosis of HHT, since the current methods are not valid for all the patients affected with HHT.
Universidad de Alcalá-OTRI posted this:Emotongue: A software for every customer with a Smartphone (Android) interested in managing their own emotions and for companies interested in their employees’ emotional healthSUMMARY Emotongue is an application for smartphones with the Android System, designed in Spanish and English, so that every customer who speaks one or both of them could easily use it every time and everywhere, having a data connection. Emotongue is not a simple app, it is the app that everybody was looking for! It had been designed for a research project carried out in the Department of Sciences of Education of the University of Alcalá, Spain, but due to its features and the great benefits it has, now it is available for every customer interested in improving his/her resources for managing his/her emotional world. Emotongue has been created for helping people to know their emotions, connect with them and learn how to manage them. The app is a tool easy to use, with a colored and dynamic design. It sends the user 5 notifications per day, and she/he has at his/her disposal 2 hours to answer each notification either by a written message or by an audio. The app is available in every country in which people speak English and/or Spanish. An improved version of the app could send users a feedback about their evolution in their management of their emotions and their use of the app. A part from the app, the authors could offer a service to companies interested in it, by creating courses about emotional management, designed according to the company’s needs, something very difficult to find in the trade market.
Consejo Superior de Investigaciones Científicas posted this:Immunoassay for rapid diagnosis of infectious diseases caused by Pseudomonas aeruginosa CSIC, CIBER-BBN and UAB have developed an immunochemical method for diagnosis of infections produced by Pseudomonas aeruginosa. The immunoassay is fast and efficient, with low LOD and adaptable to point-of care devices.
Yissum - Research Development Company of the Hebrew University posted this:Novel Naturally Occurring Compounds for Treating Cystic FibrosisCannabis project Derivatives of cannabinoids have an antimicrobial and anti biofilm effect on pseudomonas and candida which are major ethological pathogenic factors in CF Project ID : 6-2019-6720
Yissum - Research Development Company of the Hebrew University posted this:Identifying and Optimizing Treatment for Neuropathic PainIdentifying and Optimizing Treatment for Neuropathic Pain Project ID : 6-2019-9749
Ivan Rodriguez Rosello posted this:
Licensing Manager at Universidad de Alicante
Montserrat Sole Castellvi posted this:
Project Manager at Knowledge Innovation Market
Servei de Gestió de la Innovació posted this:
Licensing Manager at Universitat Politècnica de Catalunya - UPC
Consejo Superior de Investigaciones Científicas posted this:Biotechnological production of 11α hydroxylated steroids using recombinant bacteria.CSIC has developed a procedure for the biotechnological production of 11α hydroxylated steroids by generating and subsequent use of recombinant bacteria. These recombinant bacteria allow to perform microbial biotransformation processes that result in 11αhydroxylated steroid compounds from raw materials such as phytosterols and intermediate products efficiently and economically. These compounds have numerous applications in pharmacology. Companies are sought for implementing and commercializing the new technology under patent license agreement. An offer for Patent Licensing
Consejo Superior de Investigaciones Científicas posted this:Peptide for cancer control linked to IL13RR R α α 2 2 o o v v e e r r e e x x p p r r e e s s s s i i o o n n CSIC has developed a peptide capable of inhibiting the signaling of IL-13 mediated by IL13Rα2. This peptide alone or within a nanoparticle or virus-like particles can be used in a pharmaceutical composition for the treatment of pathologies in which IL13Rα2 is overexpressed. This composition would be useful in the treatment and control of metastasis of colon cancer and other tumors (i.e glioblastoma), as well as in other pathologies such as asthma, atopic dermatitis or fibrosis. Industrial partners are being sought to develop and commercialized the products through a patent licence agreement. An offer for Patent Licensing